Novartis AG (NOVN):医療機器:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7135)
◆英語タイトル:Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7135
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:225
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 13
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Novartis AG, Medical Equipment, Deal Details 23
Asset Purchase 23
GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25
SensoMotoric Sells Ophthalmic Division To Alcon Labs 26
Venture Financing 27
Pear Therapeutics Raises USD50 Million in Series B Financing 27
ImaginAb Raises USD7.7 Million in Venture Financing 29
Rani Therapeutics Raises USD39 Million in Series D Financing 30
Lemonaid Health Raises USD11 Million in Series A Financing 32
Atlas Genetics Raises USD35 Million in Series D Financing 33
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35
Rox Medical Raises USD40 Million in Series E Financing 37
Cota Raises Funds through Venture Financing 38
Rani Therapeutics Raises Funds in Financing 39
Ra Pharma Raises USD58.5 Million in Series B Financing 41
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43
MyoPowers Medical Raises USD5 Million in Venture Financing 45
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46
Autonomic Technologies Raises USD38 Million in Series D Financing 47
Merganser Biotech Raises USD28 Million in Series A Financing 49
Encore Vision Raises USD1 Million in Venture Financing 50
Atlas Genetics Raises USD20 Million in Series C Financing 51
Transcend Medical Raises USD7.2 Million in Venture Financing 53
BioNano Genomics Raises USD53 Million in Series C Venture Financing 54
Encore Vision Raises USD1.7 Million in Venture Financing 56
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57
ImaginAb Raises USD21 Million in Series B Venture Financing 59
Transcend Medical Raises US$22 Million In Series C Venture Financing 60
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 61
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 62
Encore Vision Secures USD5 Million in Venture Funding 63
Wavetec Vision Raises US$11 Million In Series D-2 Financing 64
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 65
Proteus Digital Health Raises US$63 Million In Series F Financing Round 66
Health XL Raises Funds Through Venture Financing 67
Wavetec Vision Raises US$16.5 Million In Venture Financing 68
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69
ImaginAb Raises US$12.5 Million In Series A Financing 70
WaveTec Vision Raises US$1.5 Million In Venture Financing 71
Transcend Medical Secures USD16 Million in Series B Venture Funding 72
Private Equity 73
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73
Partnerships 74
Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76
Adamis Pharma Enters into Distribution Agreement with Sandoz 77
Pear Therapeutics Enters into Agreement with Sandoz 78
Pear Therapeutics Enters into Agreement with Novartis 79
NuvoAir Enters into Agreement with Novartis 80
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81
Propeller Health Enters into Agreement with Novartis Pharma 82
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83
Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85
Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86
Novartis Enters into Agreement with Microsoft 87
MedinCell Enters into Agreement with Sandoz International 88
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89
CorTechs Labs Enters into Agreement with Novartis Pharma 90
Eveon Enters into Agreement with Advanced Accelerator Applications 91
Qiagen Enters into Co-Development Agreement with Novartis 92
SomaLogic Extends Co-Development Agreement with Novartis 93
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95
Foundation Medicine Extends Co-Development Agreement With Novartis 96
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97
Sunovion Pharma Enters into Licensing Agreement with Novartis 98
BioQuiddity Expands Licensing Agreement with Sandoz 99
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101
Life Technologies Enters Into Licensing Agreement With Novartis 102
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103
Equity Offering 104
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106
Debt Offering 108
Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108
Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109
Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 119
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 120
Asset Transactions 121
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121
Novartis Plans to Divest Assets of Alcon 122
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123
Acquisition 125
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129
Alcon Acquires Transcend Medical 131
Novartis May Acquire Genfit 132
Novartis Acquires Encore Vision 133
Novartis Acquires Ziarco Group 134
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135
Alcon Acquires WaveTec Vision Systems 136
Advanced Accelerator Applications Acquires Imaging Equipment 138
Advanced Accelerator Applications Acquires Barnatron 139
Advanced Accelerator Applications Acquires Catalana De Dispensacion 140
Novartis Acquires Vivacta For US$90 Million 141
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142
Novartis AG – Key Competitors 143
Novartis AG – Key Employees 144
Novartis AG – Locations And Subsidiaries 146
Head Office 146
Other Locations & Subsidiaries 146
Recent Developments 164
Strategy And Business Planning 164
Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 164
Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 165
Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 166
Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 167
Financial Announcements 168
Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 168
Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 173
Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 177
Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 182
Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 187
Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 191
Corporate Communications 197
Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 197
May 16, 2018: Novartis announces changes to the Executive Committee 198
May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 199
Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 200
Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 201
Dec 15, 2017: Novartis announces Oncology head to retire 202
Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 203
Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 204
May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 205
Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 206
Government and Public Interest 207
Nov 28, 2017: Biosimilar drugs have the potential to save more than USD 54 billion 207
Product News 208
Jul 12, 2018: Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community 208
Jul 09, 2018: Microsoft and Partners Showcase a New ‘Molecule’ for Better Health Outcomes 209
Jul 06, 2018: Sandoz and its affiliate, Novartis Pharmaceuticals voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance 210
Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 212
Jun 06, 2017: Alcon highlights product and service innovations at 40th BCLA, one of the largest international meetings dedicated to contact lenses 213
Other Significant Developments 215
Sep 11, 2018: Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis 215
May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 216
Sep 29, 2017: Alcon flagship AcrySof intraocular lens reaches 100 million implants and counting 217
Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 218
Mar 16, 2017: Alcon and Orbis celebrate new Flying Eye Hospital’s visit to the UK 219
Mar 03, 2017: Alcon Launches New Digital Vision Care Marketing Portal for Eye Care Professionals 220
Mar 02, 2017: Alcon Supports Eye Health with Charitable Giving of Nearly $73 Million in 2016 and Renews Commitment to Think About Your Eyes 221
Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 222
Jan 26, 2017: Achievement of sales milestone for COPD products 223
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 224
Appendix 225
Methodology 225
About GlobalData 225
Contact Us 225
Disclaimer 225

List of Tables
Novartis AG, Medical Equipment, Key Facts, 2017 2
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Deals By Market, 2012 to YTD 2018 13
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25
SensoMotoric Sells Ophthalmic Division To Alcon Labs 26
Pear Therapeutics Raises USD50 Million in Series B Financing 27
ImaginAb Raises USD7.7 Million in Venture Financing 29
Rani Therapeutics Raises USD39 Million in Series D Financing 30
Lemonaid Health Raises USD11 Million in Series A Financing 32
Atlas Genetics Raises USD35 Million in Series D Financing 33
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35
Rox Medical Raises USD40 Million in Series E Financing 37
Cota Raises Funds through Venture Financing 38
Rani Therapeutics Raises Funds in Financing 39
Ra Pharma Raises USD58.5 Million in Series B Financing 41
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43
MyoPowers Medical Raises USD5 Million in Venture Financing 45
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46
Autonomic Technologies Raises USD38 Million in Series D Financing 47
Merganser Biotech Raises USD28 Million in Series A Financing 49
Encore Vision Raises USD1 Million in Venture Financing 50
Atlas Genetics Raises USD20 Million in Series C Financing 51
Transcend Medical Raises USD7.2 Million in Venture Financing 53
BioNano Genomics Raises USD53 Million in Series C Venture Financing 54
Encore Vision Raises USD1.7 Million in Venture Financing 56
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57
ImaginAb Raises USD21 Million in Series B Venture Financing 59
Transcend Medical Raises US$22 Million In Series C Venture Financing 60
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 61
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 62
Encore Vision Secures USD5 Million in Venture Funding 63
Wavetec Vision Raises US$11 Million In Series D-2 Financing 64
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 65
Proteus Digital Health Raises US$63 Million In Series F Financing Round 66
Health XL Raises Funds Through Venture Financing 67
Wavetec Vision Raises US$16.5 Million In Venture Financing 68
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69
ImaginAb Raises US$12.5 Million In Series A Financing 70
WaveTec Vision Raises US$1.5 Million In Venture Financing 71
Transcend Medical Secures USD16 Million in Series B Venture Funding 72
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73
Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76
Adamis Pharma Enters into Distribution Agreement with Sandoz 77
Pear Therapeutics Enters into Agreement with Sandoz 78
Pear Therapeutics Enters into Agreement with Novartis 79
NuvoAir Enters into Agreement with Novartis 80
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81
Propeller Health Enters into Agreement with Novartis Pharma 82
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83
Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85
Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86
Novartis Enters into Agreement with Microsoft 87
MedinCell Enters into Agreement with Sandoz International 88
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89
CorTechs Labs Enters into Agreement with Novartis Pharma 90
Eveon Enters into Agreement with Advanced Accelerator Applications 91
Qiagen Enters into Co-Development Agreement with Novartis 92
SomaLogic Extends Co-Development Agreement with Novartis 93
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95
Foundation Medicine Extends Co-Development Agreement With Novartis 96
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97
Sunovion Pharma Enters into Licensing Agreement with Novartis 98
BioQuiddity Expands Licensing Agreement with Sandoz 99
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101
Life Technologies Enters Into Licensing Agreement With Novartis 102
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106
Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108
Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109
Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 119
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 120
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121
Novartis Plans to Divest Assets of Alcon 122
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129
Alcon Acquires Transcend Medical 131
Novartis May Acquire Genfit 132
Novartis Acquires Encore Vision 133
Novartis Acquires Ziarco Group 134
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135
Alcon Acquires WaveTec Vision Systems 136
Advanced Accelerator Applications Acquires Imaging Equipment 138
Advanced Accelerator Applications Acquires Barnatron 139
Advanced Accelerator Applications Acquires Catalana De Dispensacion 140
Novartis Acquires Vivacta For US$90 Million 141
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142
Novartis AG, Key Competitors 143
Novartis AG, Key Employees 144
Novartis AG, Subsidiaries 146

List of Figures
Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Novartis AG (NOVN):医療機器:M&Aディール及び事業提携情報(Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆